Meta-Analysis of the Clinical Effectiveness and Safety of Ligustrazine in Cerebral Infarction

Abstract EN

Objectives.

To evaluate the efficacy and safety of ligustrazine in the treatment of cerebral infarction.

Methods.

A systematic literature search was conducted in 6 databases until 30 June 2016 to identify randomized controlled trials (RCTs) of ligustrazine in the treatment of cerebral infarction.

The quality of all the included studies was evaluated.

All data were analyzed by Review Manager 5.1 Software.

Results.

19 RCTs totally involving 1969 patients were included.

The primary outcome measures were Neurological Deficit Score (NDS) and clinical effective rate.

The secondary outcome measure was adverse events.

Meta-analysis showed that ligustrazine could improve clinical efficacy and NDS of cerebral infarction with [OR = 3.60, 95% CI (2.72, 4.78), P < 0.00001 ] and [WMD = −3.87, 95% CI (−4.78, −2.95), P < 0.00001 ].

Moreover, ligustrazine in treatment group exerted better clinical effects in improving the Blood Rheology Index (BRI) in patients compared with control group.

Ten trials contained safety assessments and stated that no obvious side effects were found.

Conclusions.

Ligustrazine demonstrated definite clinical efficacy for cerebral infarction, and it can also improve NDS in patients without obvious adverse events.

However, due to the existing low-quality research, more large-scale and multicentric RCTs are required to provide clear evidence for its clinical efficacy in the near future.